Main content

Ovarian Cancer Clinical Trials

Active Trials

Title: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer
Description: Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)
Investigator: Ari Baron, MD
Eligibility: Subjects with platinum-resistant ovarian cancer
Status: Active and open to enrollment
Contact: Chrissy Raymundo, 415-600-3613, Email: RaymunCL@cpmcri.org about Study Endocyte EC-FV-06

Title: Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Pts With Ovarian or Breast Cancer
Description: MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Investigator: Ari Baron, MD
Eligibility: Female subjects, 18 y/o and older, with recurrent epithelial ovarian, fallopian tube or peritoneal cancer
Status: Coming Soon
Contact: Chrissy Raymundo, 415-600-3613, Email: RaymunCL@cpmcri.org about Study C14008 Millennium

Title: EP-100, a Novel LHRH Receptor-Targeted, Membrane-Disrupting Peptide, Plus Paclitaxel Versus Paclitaxel Alone for Refractory or Recurrent Ovarian Cancer: A Phase II, Randomized, Multi-Center Trial
Description: EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer
Investigator: Wei Wang, MD
Eligibility: Female subjects, 18 y/o and older, with refractory or recurrent ovarian cancer
Status: Coming Soon
Contact: Chrissy Raymundo, 415-600-3613, Email: RaymunCL@cpmcri.org about Study ACT12601